Impact of hydroxyurea use on severity and hematologic profile in children with sickle cell disease at University of Benin Teaching Hospital, Benin city, Nigeria
DOI:
https://doi.org/10.18203/2349-3291.ijcp20262406Keywords:
Disease severity, Hydroxyurea, Sickle cell anaemia, Packed cell volume, White blood cell countAbstract
Background: Sickle cell disease (SCD) is a major cause of morbidity and mortality among children in sub-Saharan African. Hydroxyurea (HU) remains the cornerstone of disease- modifying therapy, but its utilization, hematologic impact and relationship with disease severity among Nigerian children are not fully characterized. This study assessed the impact of hydroxyurea use on disease severity and haematologic profile in children with SCD attending the University of Benin of teaching Hospital, Benin city.
Methods: This cross- sectional study included 225 children with SCA aged 1-18 years in steady state. Data were obtained on socio- demographic characteristics, HU use and disease severity were using structured proforma and medical records. Disease severity was assessed using Adegoke’s scoring system while haematologic parameters including Packed cell volume and White blood cell counts were documented. Statistical associations between HU, hematologic indices and disease severity were analysed using Chi-square tests, with significance set at p<0.05.
Results: The mean age was 9.5±4.5 years: 57.8% were male and 57.3% belonged to the middle socioeconomic class. Most patients had mild (51.1%) or moderate (47.6%) disease with severe disease in only 1.3%. disease severity was significantly associated with gender (p=0.029). Hydroxyurea use was high (61.3%), more frequent in females (p=0.032). HU use was significantly associated with disease severity (ꭓ2=9.422; p=0.009). Higher PCV was linked with milder disease (p= 0.004) whereas elevated WBC counts were associated with more severe disease (p<0.001).
Conclusions: HU therapy, higher PCV and lower WBC counts are associated with milder disease among children with SCD. These findings reinforce Hydroxyurea clinical benefits and highlight the value of simple haematologic indices for disease monitoring in resource poor settings.
References
Wastnedge E, Waters D, Patel S, Morrison K, Goh M, Adeloye D. The global burden of sickle cell disease in children under five years of age: a systematic review and meta-analysis. J Glob health. 2018;8:021103.
Harris JW. Studies on the destruction of red cells. VIII. Molecular orientation in sickle cell haemoglobin solutions. Pro Soc Exp Biol Med. 1990;75:197-201.
Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusion for the prevention of recurrent stroke in children with sickle cell disease. Blood.1999;94:3022-6.
Adeodu OO, Adegoke SA, Owa JA, Elusiyan JB. Foetal haemoglobin and disease severity in Nigerian children with sickle cell anaemia. Mediterr J Hematol Infect Dis. 2017;9(1):e2017063.
Adewoyin AS, Alagbe AE, Adedokun BO, Idubor NT. Hydroxyurea therapy in sickle cell disease in Nigeria: A multicentre survey of utilization and safety. J Clin Exp Hematop. 2017;57(2):73-9.
Adigun TA, Olatunji PO, Akintunde AA. Patterns and outcomes of hydroxyurea use among sickle cell disease patients in a tertiary hospital in Nigeria. Nig J Clin Pract. 2019;22(5):633-9.
Joseph EB, Eke CB, Ibeziako N. Hydroxyurea and fertility in sickle cell disease: A narrative review. Pediatr Blood Cancer. 2021;68(3):e28820.
Charache S, Terrin ML, Moore RD. Effect of Hydroxyurea on the frequency of painful crises in sickle cell anaemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle cell anaemia. N Engl J Med. 1995;332:1317-22.
Adegoke SA, Kuti BP. Evaluation of clinical severity of sickle cell anaemia in Nigerian Children. J Appl Haematol. 2013;4(2):58-64.
Oyedeji GA. Socioeconomic and cultural background of hospitalised children in Ilesha. Niger J Paediatr. 1985;12:111-7.
Nnajekwu UC, Nnajekwu CO, Onukwuli VO, Uwaezuoke NA, Ezenwosu OU, Ikefuna AN, et al. Relationship between disease severity and folate status of children with sickle cell anaemia in Enugu, South East Nigeria. Afri Health Sci. 2021;21(2):759-64.
Al-Saqladi AW, Bin-Gadeem HA, Brabin BJ. Clinical profile of sickle cell disease in Yemeni children. Ann Trop Paediatr. 2007;27(4):253-9.
Ezeuko LC, Odunvbun ME, Ikejiaku UP, Ike II, Anthony-Eweputanna SA, Ezerioha OP, et al. Relationship between Cerebral artery blood flow velocities and Sickle cell severity. J Med Africa. 2024;7(2):55-62.
Olasinde YT, Ibrahim RO, Abolarin A, Odeyemi AO. Disease severity of Children Attending the paediatric Sickle cell Clinic of a tertiary health institution in Southwest Nigeria. Niger J of Basic Clin Sci; 2024;21(1):52-7.
Chianumba R, Okpala I, Gordeuk VR. Hydroxyurea therapy uptake in Nigerian patients with Sickle cell disease: A multicentre study. Hematology. 2020;25(1):123-31.
Tshilolo L, Tomlinson G, Williams TN, Santos B, Olupot-Oluput P, Lane A. Hydroxyurea for children with sickle cell anaemia in sub-Saharan Africa (REACH). N Engl J Med. 2019;380(2):121-31.
Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Phillip A, Vincent O, et al. Steady state haemoglobin concentration and packed cell volume in homozygous sickle cell disease patients in Lagos, Nigeria. Caspian J Intern Med. 2012;3(4):405-9.
Abdullahi SU, Aliyu ZY, Galadanci H. Hydroxyurea for secondary stroke prevention in children with sickle cell anaemia in low-resource settings. Blood. 2022;139(10):1536-45.
Lagunju I, Brown BJ, Sodeinde O. Hydroxyurea lowers transcranial flow velocities in children with sickle cell anaemia in a Nigerian cohort. Pediatr Blood Cancer. 2015;62:1587-91.
Akinsete A. Experience with hydroxycarbamide use; indications, adverse effects and clinical course at a tertiary hospital in Lagos. Nig Qrtly J Hosp Med. 2019;28:26-30.
Ofakunrin OAD, Adekola KU, Oguche S, Okpe ES, Sagay AS. Efficacy and safety of hydroxyurea in the treatment of sickle cell disease in Jos, Nigeria. J Trop Pediatr. 2019;66:290-8.
Oni NO, Ogundeyi MM, Iyabo OD, Adebola MB, Olanrewaju DM. The Impact of Hydroxyurea on Clinical and Haematological Parameters in Children with Sickle cell Anaemia. Nig J Paediatr. 2024;3:265-77.
Kinney TR, Helms RW, O’Branski EE. Safety of hydroxyurea in children with sickle cell anaemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94:1550-4.
Downloads
Published
How to Cite
Issue
Section
